Steady growth in key markets of the US and India has helped drug major Lupin Ltd post 40 per cent growth in net profit for the quarter ended June 30. The net profit for the quarter was Rs 196.3 crore against Rs 140.1 crore during the comparable period last year.
Net revenues during the quarter stood at Rs 1,334.28 crore, 21 per cent higher than Rs 1,100.54 crore recorded during the same period last financial year, the company announced today.
"The US and Indian markets, which account for about 65 per cent of our sales, showed strong growth. Japan, our third largest market with 10 per cent of sales, also did well”, Lupin MD Kamal Sharma said, adding the company has been maintaining the growth momentum for the last 17 quarters.
